Rare Genetic Variants in Complement Factor I Lead to Low FI Plasma Levels Resulting in Increased Risk of Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

Rare Genetic Variants in Complement Factor I Lead to Low FI Plasma Levels Resulting in Increased Risk of Age-Related Macular Degeneration

Published:2020-06-09 Issue:6 Volume:61 Page:18
ISSN:1552-5783
Container-title:Investigative Opthalmology & Visual Science
language:en
Short-container-title:Invest. Ophthalmol. Vis. Sci.

Author:

Hallam Thomas M.¹²³,Marchbank Kevin J.¹²,Harris Claire L.¹²,Osmond Clive⁴,Shuttleworth Victoria G.¹²,Griffiths Helen³,Cree Angela J.³,Kavanagh David¹²,Lotery Andrew J.³

Affiliation:

1. Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

2. National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom

3. Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom

4. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom

Publisher

Association for Research in Vision and Ophthalmology (ARVO)

Subject

General Medicine

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ocular biomarker profiling after complement factor I gene therapy in geographic atrophy secondary to age-related macular degeneration;2024-09-05

2. Ocular biomarker profiling after complement factor I gene therapy in geographic atrophy secondary to age-related macular degeneration;2024-09-05

3. Comprehensive functional characterization of complement factor I rare variant genotypes identified in the SCOPE geographic atrophy cohort;Journal of Biological Chemistry;2024-07

4. Ocular biomarker profiling after complement factor I gene therapy in geographic atrophy secondary to age-related macular degeneration;2024-06-13

5. Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investment;Progress in Retinal and Eye Research;2024-03